16 Aug 2019 13:51
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director and other PDMR Dealings
London, August 16, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on August 15, 2019, Charles Sermon, General Counsel, purchased 6355 Ordinary Shares at a price of GBP0.54 per share. Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 6000 Ordinary Shares at a price of GBP0.54 per share. John Richard, Head of Corporate Development at Mereo, purchased 1500 American Depositary Shares (ADSs) at a price of USD3.31 per ADS.
On August 16, 2019 Denise Scots-Knight, Chief Executive Officer of Mereo, also purchased 6000 Ordinary Shares at a price of GBP0.54 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 | Details of the person discharging managerial responsibilities
| |||||
a) | Name | Charles Sermon
| ||||
2 | Reason for the notification | |||||
a) | Position/status | General Counsel
| ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc
| ||||
b) | LEI | 213800U8JQHIJOS5AS09
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH | ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 6355 Aggregated price: GBP0.535 | ||||
e) | Date of the transaction | 2019-08-15 | ||||
f) | Place of the transaction | AIMX | ||||
1 | Details of the person discharging managerial responsibilities
| |||||
a) | Name | Denise Scots-Knight
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer
| ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc
| ||||
b) | LEI | 213800U8JQHIJOS5AS09
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH | ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 6000 Aggregated price: GBP0.54 | ||||
e) | Date of the transaction | 2019-08-15 | ||||
f) | Place of the transaction | AIMX | ||||
1 | Details of the person discharging managerial responsibilities
| |||||
a) | Name | Denise Scots-Knight
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer
| ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc
| ||||
b) | LEI | 213800U8JQHIJOS5AS09
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH | ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 6000 Aggregated price: GBP0.535 | ||||
e) | Date of the transaction | 2019-08-16 | ||||
f) | Place of the transaction | AIMX | ||||
1 | Details of the person discharging managerial responsibilities
| |||||
a) | Name | John Richard
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Head of Corporate Development
| ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc
| ||||
b) | LEI | 213800U8JQHIJOS5AS09
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH | ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 1500 Aggregated price: USD3.313 | ||||
e) | Date of the transaction | 2019-08-15 | ||||
f) | Place of the transaction | XNMS | ||||